Objective. To examine the allelic association of the single nucleotide polymorphism (CTLA4AuG ) in exon 1 of the cytotoxic T lymphocyte antigen-4 (CTLA4 ) gene with early rheumatoid arthritis (RA).
Rheumatoid arthritis (RA) is a common autoimmune inflammatory disorder that is usually associated with progressive joint destruction. Although the pathogenesis of RA is unknown, the higher concordance of RA in monozygotic twins (15.4 vs 3.6% concordance in dizygotic twins) w1x and the familial clustering provide evidence for the role of genetic factors in the pathogenesis of this disorder. It is estimated that a sibling of an RA proband is between five and eight times more likely to develop this disorder than a member of the general population (sibling risk ratio, l s = 5-8) w2, 3x. Prospective studies have shown that 15-20% of RA subjects have overt autoimmune thyroid disease (AITD) w4, 5x, and there is also known to be an excess prevalence of type 1 diabetes mellitus (IDDM) in RA patients and their families w6x, suggesting that these disorders may have a common genetic susceptibility. A recent genomewide linkage analysis in RA has confirmed that the human leukocyte antigen (HLA) complex, which has been found to be associated with RA in many casecontrol studies, is a major susceptibility locus for RA w3x. It has been shown that HLA may confer up to one-third of the total genetic susceptibility to RA (HLA locus-specific l s = 1.7) w3x. Moreover, evidence for several non-HLA susceptibility loci has also been reported, which confirms that RA, like the majority of autoimmune disorders, is a complex multigenic trait w2, 3x.
The cytotoxic T-lymphocyte antigen 4 (CTLA4) is a costimulatory molecule that is expressed on activated T lymphocytes and is an important negative regulator of T-cell activation. Thus, the CTLA4 gene, which is located on chromosome 2q33, is a candidate locus for RA and other autoimmune disorders. Indeed, this locus has been found to show linkage and association with several autoimmune disorders, including IDDM and AITD w7-11x. Although previous case-control studies in different populations have suggested a possible association of CTLA4 alleles with RA, the results of these studies are not conclusive and are sometimes contradictory w12-15x. In the present study, we demonstrate an association between the G allele of the CTLA4 exon 1 polymorphism (CTLA4AuG) and RA, which is explained largely by the presence of coexisting autoimmune endocrinopathies.
Patients and methods

Patients
Consecutive patients referred to our rheumatology outpatient service with inflammatory arthritis were screened to identify individuals who fulfilled the 1987 modified criteria for RA w16x and in whom the interval from the onset of persistent symptoms was less than 2 yr. One hundred and twenty-three white patients were recruited. The Westergren erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) concentration and rheumatoid factor were analysed at presentation. Rheumatoid factor was analysed with a particle agglutination kit (Fujirebio, Tokyo, Japan), and final dilution titres of 1 : 40 and above were interpreted as positive. Radiographs of the hands and feet were taken at presentation and were read by an independent radiologist to determine the presence or absence of erosions. We also studied 349 local white subjects without clinical evidence or a family history of autoimmune disease as controls. The majority of these subjects were recruited from the general population from the patient register of the Newcastle Family Health Services Authority, and 92 were general out-patients with non-autoimmune disorders. Studies were carried out with the approval of the district ethics committee.
CTLA4 genotyping
Genomic DNA was obtained from venous blood from each subject using the BACCII kit (Nucleon Biosciences, Glasgow, UK). The CTLA4AuG polymorphism, which encodes a threonine (GCC) to alanine (ACC) substitution at codon 17 in exon 1 of the CTLA4 gene, was amplified by the polymerase chain reaction (PCR) from genomic DNA followed by digestion with the restriction enzyme Bst71I (Promega, Southampton, UK), as described previously w9x. The primers were 59-CCA CGG CTT CCT TTC TCG TA-39 (forward) and 59-AGT CTC ACT CAC CTT TGC AG-39 (reverse). The restriction enzyme Bst71I cuts the 328 base pair (bp) PCR product only if the G allele is present at this site, resulting in fragments of 244 and 84 bp, which were resolved on a 2.5% agarose gel.
HLA DRB1*01 and DRB1*04 typing Typing for the HLA DRB1*01 (DR1) and HLA DRB1*04 (DR4) alleles was performed in our laboratory using methods, primers and controls obtained from the Tissue Typing Laboratory at the Northern Regional Blood Transfusion Centre, Barrack Road, Newcastle-upon-Tyne. The method involved PCR with sequence-specific oligonucleotide primers. HLA DRB1*01 was genotyped with the primers 59-TTG TGG CAG CTT AAG TTT GAA T-39 and 59-CCG CCT CTG CTC CAG GAG-39. These identify the DRB1* alleles 0101, 01021, 01022 and 0104. Similarly, HLA DRB1*04 (DR4) was genotyped with the primers 59-GTT TCT TGG AGC AGG TTA AAC A-39, 59-CTG CAC TGT GAA GCT CTC AC-39 and 59-CTG CAC TGT GAA GCT CTC CA-39. These identify the DRB1* alleles 04011-0407, 0410-0412, 0415-0417, 0421, 0422, 0424, 0425, 1122, 1410, 0419, 0420 and 0423.
Statistical analysis
Comparisons of the allele frequencies at the CTLA4AuG polymorphism between patient and control groups were performed using Fisher's exact test on 2 3 2 contingency tables. Odds ratios (OR) and 95% confidence intervals (CI) were calculated with Woolf 's method. The relationships of CTLA4AuG genotype with ESR and CRP level at presentation were analysed with the Mann-Whitney U-test. GraphPad Prism version 2.01 was used to compute these statistical analyses.
Results
We genotyped 123 subjects with early RA and 349 controls for the CTLA4AuG polymorphism. The demographic and clinical characteristics of the early RA patients are shown in Table 1 . Nineteen (15%) of these patients had a history of coexistent autoimmune endocrinopathies (AITD or IDDM).
We found a significantly increased frequency of the G allele of the CTLA4AuG polymorphism in early RA subjects compared with controls (P = 0.028 vs controls, OR 1.35, 95% CI 1.01-1.82) ( Table 2 ). In the 19 RA subjects with coexisting autoimmune endocrinopathy (AITD or IDDM), there was a strong association with the CTLA4 G allele (58 vs 36% in controls, P = 0.005, OR 2.50, 95% CI 1.29-4.84) ( Table 3 ). In a smaller subgroup of 13 patients with endocrinopathy, who were also DR1-or DR4-positive, the G allele frequency was 65 vs 36% in controls (P = 0.002, OR 3.43, 95% CI 1.51-7.81). The prevalence of the CTLA4 G allele amongst the RA subjects with autoimmune endocrinopathy was significantly different from that of RA subjects without endocrinopathy (58 vs 40%; P = 0.030, OR 2.07, 95% CI 1.03-4.18). The CTLA4 G allele frequency of RA subjects without endocrinopathy was not significantly different from that of controls (40 vs 36%, P = 0.140).
In the patients with radiological evidence of erosions at presentation, the G allele frequency was 46% compared with 41% (P = 0.28) in those who had normal X-rays. There was no significant difference in the G allele frequency between DR1u4-positive and DR1u4-negative RA subjects (Table 3) . No significant differences were found in the G allele frequency between male and female patients (50 vs 39%, P = 0.11), or between patients positive or negative for rheumatoid factor (47 vs 41%, P = 0.216). No association was found between different genotypes of the CTLA4 polymorphism and ESR or CRP values measured at the time of presentation (data not shown).
Discussion
Our study shows that the G allele of the CTLA4AuG polymorphism is more prevalent in early RA patients than in controls (P = 0.028). However, this finding is explained largely by the strong association of the G allele with autoimmune endocrinopathies in our cohort (Table 3) . In contrast to the four previous studies of the CTLA4AuG polymorphism in RA w12-15x, the present study took account of the autoimmune endocrinopathies, which are known to be independently associated with CTLA4 alleles w7-11x. The association of RA with CTLA4 alleles reported in other RA cohorts may also be due to cases of coexisting AITD or IDDM w12-14x. Seidl et al. w12x reported a significant increase in the G allele frequency in German RA patients who were positive for the HLA-DRB1*0401 allele w12x. In a similar Spanish study, a significant increase in AuG heterozygosity for the CTLA4AuG polymorphism was found only in HLA-DR3-positive subjects, particularly in DR3-positive women w13x. These reports of apparent CTLA4 association within HLA subgroups of RA patients could also be explained by the known associations of HLA DR3 and DR4 alleles with AITD and IDDM respectively.
There are other possible reasons for the discrepancies observed between our study and previous CTLA4 association studies w12-15x. Case-control studies are very sensitive to the selection of an appropriate control population. In the study of Barton et al. w15x, which found no association between CTLA4 alleles and RA, the G allele frequency in the UK controls (ethnicity not detailed) is given as 46%. This is much higher than the G allele frequencies in the UK white controls seen in our present study (36%) and in another large UK study (32%) w10x. Furthermore, Barton et al. derived their patients from a pan-UK national repository, whilst our patients are from a stable population in a more limited geographical area and are likely to be more genetically homogeneous. Nevertheless, it is interesting to note that the G allele frequency in our RA group (43%) is similar to that found by Barton's study (42%) w15x. However, the loci for complex multigenic disorders may make different contributions to disease susceptibility in populations of diverse origins. Such genetic heterogeneity in different white populations has been demonstrated previously for CTLA4 in IDDM and Graves' disease w8, 9x, and similar heterogeneity may be present in RA.
Though associated with a number of autoimmune diseases, this CTLA4AuG polymorphism, which encodes a threonine to alanine change within the signal peptide of CTLA-4, has an unknown function. However, (n = 45) (n = 78) (n = 19) (n = 104) (n = 84) (n = 39) n (%) n (%) n (%) n (%) n (%) n (%) 
